EP2114903A4 - Pyrimidinones bicycliques et utilisations de celles-ci - Google Patents

Pyrimidinones bicycliques et utilisations de celles-ci

Info

Publication number
EP2114903A4
EP2114903A4 EP07855368A EP07855368A EP2114903A4 EP 2114903 A4 EP2114903 A4 EP 2114903A4 EP 07855368 A EP07855368 A EP 07855368A EP 07855368 A EP07855368 A EP 07855368A EP 2114903 A4 EP2114903 A4 EP 2114903A4
Authority
EP
European Patent Office
Prior art keywords
bicyclic pyrimidinones
pyrimidinones
bicyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP07855368A
Other languages
German (de)
English (en)
Other versions
EP2114903A1 (fr
EP2114903B1 (fr
Inventor
Eric Dale Jones
Jonathan Alan Victor Coates
David Ian Rhodes
John Joseph Deadman
Nicholas Andrew Vandegraff
Lisa Jane Winfield
Neeranat Thienthong
William Issa
Neil Choi
Katherine Macfarlane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tali Digital Ltd
Original Assignee
Avexa Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006907283A external-priority patent/AU2006907283A0/en
Application filed by Avexa Ltd filed Critical Avexa Ltd
Priority to EP10164218A priority Critical patent/EP2269992A1/fr
Publication of EP2114903A1 publication Critical patent/EP2114903A1/fr
Publication of EP2114903A4 publication Critical patent/EP2114903A4/fr
Application granted granted Critical
Publication of EP2114903B1 publication Critical patent/EP2114903B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP07855368A 2006-12-22 2007-12-21 Pyrimidinones bicycliques et utilisations de celles-ci Active EP2114903B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10164218A EP2269992A1 (fr) 2006-12-22 2007-12-21 Pyrimidinones bicycliques pour le traitement des infections

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2006907283A AU2006907283A0 (en) 2006-12-22 Bicyclic pyrimidinones and uses thereof
AU2007902479A AU2007902479A0 (en) 2007-05-09 Bicyclic pyrimidinones and uses thereof (2)
AU2007903401A AU2007903401A0 (en) 2007-06-25 Bicyclic pyrimidinodes and uses thereof (3)
AU2007904114A AU2007904114A0 (en) 2007-07-31 Bicyclic pyrimidinones and uses thereof (4)
PCT/AU2007/001980 WO2008077188A1 (fr) 2006-12-22 2007-12-21 Pyrimidinones bicycliques et utilisations de celles-ci

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP10164218.9 Division-Into 2010-05-28

Publications (3)

Publication Number Publication Date
EP2114903A1 EP2114903A1 (fr) 2009-11-11
EP2114903A4 true EP2114903A4 (fr) 2009-12-30
EP2114903B1 EP2114903B1 (fr) 2011-01-26

Family

ID=39562030

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07855368A Active EP2114903B1 (fr) 2006-12-22 2007-12-21 Pyrimidinones bicycliques et utilisations de celles-ci
EP10164218A Withdrawn EP2269992A1 (fr) 2006-12-22 2007-12-21 Pyrimidinones bicycliques pour le traitement des infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP10164218A Withdrawn EP2269992A1 (fr) 2006-12-22 2007-12-21 Pyrimidinones bicycliques pour le traitement des infections

Country Status (15)

Country Link
US (3) US8143268B2 (fr)
EP (2) EP2114903B1 (fr)
JP (2) JP5208962B2 (fr)
KR (2) KR20090097194A (fr)
CN (1) CN101880280B (fr)
AR (2) AR064517A1 (fr)
AT (1) ATE496898T1 (fr)
AU (2) AU2007336703B9 (fr)
BR (2) BRPI0720564A2 (fr)
CA (1) CA2673183C (fr)
DE (1) DE602007012308D1 (fr)
DK (1) DK2114903T3 (fr)
MX (1) MX2009006764A (fr)
NZ (1) NZ577491A (fr)
WO (1) WO2008077188A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318732B2 (en) * 2008-07-02 2012-11-27 Avexa Limited Compounds having antiviral properties
WO2010000031A1 (fr) * 2008-07-02 2010-01-07 Avexa Limited Imidazopyrimidinones et leurs utilisations
EP2247601B1 (fr) * 2008-07-02 2013-04-10 Avexa Limited Thiazopyrimidinones et leurs utilisations
CN102336751A (zh) * 2010-07-16 2012-02-01 爱维艾珂瑟有限公司 新型抗病毒剂
CN105764904B (zh) 2013-09-12 2020-02-11 詹森生物制药有限公司 氮杂-吡啶酮化合物及其用途
WO2015105657A1 (fr) * 2013-12-19 2015-07-16 Ptc Therapeutics, Inc. Procédés pour moduler la quantité de transcrits d'arn
WO2016145103A1 (fr) 2015-03-11 2016-09-15 Alios Biopharma, Inc. Composés d'aza-pyridone et leurs utilisations
EP3310169B1 (fr) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Procédés de modulation de l'épissage de l'arn
CA3119019C (fr) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Composes et methodes pour traiter la maladie de huntington
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａスプライシングを調節する方法
EP4151627A1 (fr) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Composés permettant de traiter la maladie de huntington
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (fr) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Composés hétéroaryles pour le traitement de la maladie de huntington
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
CA3139821A1 (fr) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Composes pour le traitement de la maladie de huntington
US12195458B2 (en) 2019-12-02 2025-01-14 Storm Therapeutics Limited Polyheterocyclic compounds as METTL3 inhibitors
US12070445B2 (en) * 2021-08-27 2024-08-27 Wisconsin Alumni Research Foundation System and assay for monitoring production/release of membrane-lytic toxins in bacteria and compounds for modulating same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044141A2 (fr) 2000-09-20 2002-06-06 Schering Corporation Imidazoles substituees utilisees comme agonistes ou antagonistes doubles d'histamine h1 et h3
US7176220B2 (en) 2002-11-20 2007-02-13 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as pharmaceutical agent
ATE435222T1 (de) 2003-12-18 2009-07-15 Tibotec Pharm Ltd Aminobenzimidazole und benzimidazole als inhibitoren der replikation von respiratory syncytial virus
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
MX2007004403A (es) 2004-10-12 2007-04-27 Astrazeneca Ab Derivados de quinazolina.
WO2006103399A1 (fr) 2005-03-31 2006-10-05 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Inhibiteurs de l’integrase du vih
JP5094725B2 (ja) 2005-10-04 2012-12-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｈｉｖインテグラーゼ阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
AU2007336703B9 (en) 2014-03-27
AU2010201160A1 (en) 2010-04-15
JP2010513322A (ja) 2010-04-30
EP2114903A1 (fr) 2009-11-11
MX2009006764A (es) 2009-11-26
AR077043A2 (es) 2011-07-27
JP2010222370A (ja) 2010-10-07
CN101880280A (zh) 2010-11-10
WO2008077188A1 (fr) 2008-07-03
US20120232035A1 (en) 2012-09-13
EP2114903B1 (fr) 2011-01-26
US20100168063A1 (en) 2010-07-01
CN101880280B (zh) 2014-07-16
EP2269992A1 (fr) 2011-01-05
BRPI0720564A2 (pt) 2011-08-16
ATE496898T1 (de) 2011-02-15
AR064517A1 (es) 2009-04-08
US8859563B2 (en) 2014-10-14
KR20090097194A (ko) 2009-09-15
BRPI0722411A2 (pt) 2012-06-05
US8207334B2 (en) 2012-06-26
KR20100049698A (ko) 2010-05-12
CA2673183A1 (fr) 2008-07-03
AU2007336703B2 (en) 2012-04-12
HK1131615A1 (en) 2010-01-29
DK2114903T3 (da) 2011-04-18
DE602007012308D1 (de) 2011-03-10
US8143268B2 (en) 2012-03-27
US20110009366A1 (en) 2011-01-13
NZ577491A (en) 2011-06-30
JP5208962B2 (ja) 2013-06-12
AU2007336703A1 (en) 2008-07-03
CA2673183C (fr) 2014-06-10

Similar Documents

Publication Publication Date Title
EP2068869A4 (fr) Nouveaux imidazothiazoles et imidazoxazoles
ZA200810323B (en) Fkbp-l and uses thereof
TWI561237B (en) Substituted dihydropyrazolones and their use
IL244442B (en) Compounds of converted acylanilides and their use
PL2064327T3 (pl) Dbait i ich zastosowania
IL195658A0 (en) Anti-nkg2a antibodies and uses thereof
ZA200809382B (en) Pyrrolopyrimidine compounds and their uses
IL196397A0 (en) Prlr-specific antibody and uses thereof
PL2099826T3 (pl) Przeciwciało przeciwko beta-amyloidowi i jego zastosowania
ZA200903906B (en) Carboranylporphyrins and uses thereof
GB0621160D0 (en) Compounds and uses thereof
EP2124908A4 (fr) Composés et utilisations de ceux-ci
EP2120563A4 (fr) Composés et leurs utilisations
IL198809A0 (en) Substituted quinazolines
EP2097446A4 (fr) Antagonistes de la resistine et leurs utilisations
ZA200904321B (en) Bicyclic pyrimidinones and uses thereof
EP2099459A4 (fr) Composés et leurs utilisations
EP1984931A4 (fr) Agencement de bouton-poussoir et bouton-poussoir
GB0623749D0 (en) Substituted quinazolines
AU2006907283A0 (en) Bicyclic pyrimidinones and uses thereof
EP2120957A4 (fr) Composés et leurs utilisations
GB0610059D0 (en) Uses and methods
AU2007904114A0 (en) Bicyclic pyrimidinones and uses thereof (4)
AU2007902479A0 (en) Bicyclic pyrimidinones and uses thereof (2)
GB2444960B (en) Combined pseudoscope and hyperscope

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20091127

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131615

Country of ref document: HK

17Q First examination report despatched

Effective date: 20100205

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602007012308

Country of ref document: DE

Date of ref document: 20110310

Kind code of ref document: P

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007012308

Country of ref document: DE

Effective date: 20110310

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BRAUNPAT BRAUN EDER AG

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2358550

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20110428

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20110126

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20110126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110126

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110427

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110526

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110126

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110526

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1131615

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110126

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110126

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110426

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110126

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110126

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110126

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110126

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110126

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110126

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110126

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20111027

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007012308

Country of ref document: DE

Effective date: 20111027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110126

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20141201

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20141202

Year of fee payment: 8

Ref country code: DE

Payment date: 20141202

Year of fee payment: 8

Ref country code: SE

Payment date: 20141201

Year of fee payment: 8

Ref country code: ES

Payment date: 20141201

Year of fee payment: 8

Ref country code: GB

Payment date: 20141127

Year of fee payment: 8

Ref country code: IE

Payment date: 20141201

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20141207

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20141219

Year of fee payment: 8

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007012308

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20151231

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20151221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151222

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20160831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160701

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151231

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151221

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151222

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20180705